ClinicalTrials.gov
public full text
Public Domain
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven participant cohorts for up to 603 previously treated and treatment-naïve NSCLC participant. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation#884164
- Gefitinib Combined With Thalidomide to Treat NSCLC#1128252
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)#802082
- Ponatinib in Advanced NSCLC w/ RET Translocations#1140055
- Therapy for Advanced NSCLC With EGFR 19delins Mutation#1150864
Record · ID 837130
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive